- Avricore recently launched HealthTab, its point-of-care testing platform, in 12 Shoppers Drug Mart stores as well as in several independent pharmacies in Canada
- Speaking in a recent PBA à Noon podcast, Avricore CEO Hector Bremner outlined several benefits and capabilities of the platform
- HealthTab processes patients’ diagnostics and biometric data to generate easy-to-read personalized reports that patients and professionals can use to guide care plans
- It can also power third-party health tech products with real-world results and diagnostics as it is built on an open API platform
Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is disrupting and revolutionizing the pharmacy practice through its proprietary solution that combines various novel elements and enables users to enjoy a plethora of benefits at a lower cost. This was part of the message company CEO Hector Bremner delivered during a recent
PBA à Noon podcast episode hosted by Paul Benwell & Associates (
https://ibn.fm/B4x3F).
Bremner was describing Avricore’s point-of-care testing platform, HealthTab(TM), which was recently launched in 15 Shoppers Drug Mart stores located in the Greater Toronto Area and in several independent pharmacies in British Columbia and Ontario (
https://ibn.fm/aSKLh).
“HealthTab sources the best point-of-care analyzers and brings them onto a single, secure cloud-based network. It gives patients and pharmacies access to results on the spot and makes de-identified data available in real-time. This harmonized model for community-based testing is the first of its kind, making Avricore the clear leader in this rapidly emerging space,” reads the company’s presentation (
https://ibn.fm/8RwEG).
In describing exactly what HealthTab is, Bremner delineated the platform’s functionality. Everything begins when the patient provides consent and answers a customized health survey when creating an account, either online or within the store. While at the store, the integrated on-site lab-accurate testing device collects the patient’s diagnostics information. The HealthTab system then merges the data from the survey and testing device, processes it using complex calculations to filter the biometric and diagnostic data of the patient, and then generates personalized reports.
“And so, the power of HealthTab is that it is able to greatly reduce the amount of administration time, extract the result directly out of the machine, merge information, do the complex calculations in order to properly interpret the data, and then produce it in an easy to read format that the patient and professional can interpret quickly and understand the result and then use that to guide their care plan,” Bremner continued.
In addition to these benefits and capabilities, HealthTab boasts a de-identified real-time data attribute that can enable researchers, drug makers, governments, and NGOs to use the platform to conduct studies and research in real-time, real-world settings in community pharmacies. Although de-identification, while desirable, is not a new concept, it is done on an ad hoc basis, according to Bremner.
“It’s been largely due to lack of infrastructure and the type and costing of that type of testing that has been available to them in the pharmacy,” explained Bremner. “However, HealthTab is the breakthrough. We’ve simplified it, made it easy, and affordable.”
Built on an open API platform, HealthTab can connect to other B2B or B2C health data-focused software. As a result, the platform, which supports easy and quick data transfers, can power third-party health tech products with real-world results and direct diagnostics from pharmacies. HealthTab also has a “fantastic interface” that allows individual patients to seamlessly navigate the platform.
Through the various features packed into HealthTab, Avricore is empowering patients along a healthier path.
For more information, visit the company’s website at
www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at
https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.